Navigation Links
Targeting nerve growth factor may cure liver cancer
Date:9/6/2007

Nerve growth factor (NGF), as the name says, is an essential peptide factor for the growth and differentiation of neuronal cells. Therefore we can imagine that this growth factor is important for the nervous system including brain. But a recent scientific report published in the October 7 issue of the World Journal of Gastroenterology tells us another surprising and exciting discovery about this growth factor: NGF is positively related with liver cancer, the No.2 killer among all kinds of cancers in the world.

This research was collaboration among scientists from National Research Council of Italy, Marino Hospital in Rome, Regina Elena Cancer Institute in Rome, and University of Rome. This fruitful collaboration was under the leadership of Dr Annalucia Serafino, a talented biologist who has made her well-recognized reputation in cancer research and hepatitis C virus research. She is holding a senior researcher position in the national research council in Rome, which plays a similar role as the National Institutes of Health in the United States.

With many beautiful pictures of immunohistology, these scientists showed that NGF and its receptor trkANGF were expressed in the liver of the patients troubled with liver cirrhosis and/or hepatocellular carcinoma (HCC) while these two molecules are not detected in the liver of healthy people. For a growth factor to affect a cell, there should be its specific receptor expressed on the surface of the target cell. Since both NGF and its specific receptor are abnormally expressed in the liver of patients, NGF seems to be expressed by liver cells to affect themselves (so called autocrine) or to affect adjacent cells (so called paracrine) in patients with liver cirrhosis and/or HCC.

These important discoveries indicate that NGF is playing a critical role in the development of liver cirrhosis and its progression towards HCC. Based on this discovery, targeting the NGF or its specific receptor trkANGF i
'/>"/>

Contact: Lixin Zhu
wjg@wjgnet.com
86-108-538-1892
World Journal of Gastroenterology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers discover stem cell guide that may be key for targeting neural stem cell treatments
2. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
3. Pain killer fights breast cancer by targeting key enzyme
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting tumors the natural way
6. Targeting sugar on blood vessels may inhibit cancer growth
7. Wisconsin scientists grow critical nerve cells
8. Clam embryo study shows pollutant mixture adversely affects nerve cell development
9. Zebrafish may hold key to understanding human nerve cell development
10. New component of the brakes on nerve regeneration found
11. Cerebral navigation: How do nerve fibers know what direction to grow in?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... N.Y. A billion people living in underdeveloped areas ... that survive by residing in and feeding on their ... systemic) illnesses leading to long-term disability. Irah King and ... investigating illnesses caused by these gut-dwelling worms in an ...
... Mo. Americans spend $25 billion a year on ... While the Nutrition Business Journal forecasts that sales of ... over the next five years, scientists still don,t know ... harmful to humans. Now, with a new $7.5 million ...
... Max Planck Institute for Chemical Ecology in Jena, Germany, ... pending for 40 million years. Arum palaestinum ... flies) as pollinators by emitting odor molecules that resemble ... by yeast. The plant accomplishes the illusion of yeast ...
Cached Biology News:Studying illnesses caused by worms: Scientists are learning how immune cells communicate 2MU establishes National Botanical Research Center 2Deceitful lily fools flies 2Deceitful lily fools flies 3
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... 2015 US-Australian drug discovery company, Novogen Limited ... is committed to progressing its ground-breaking technology platforms to ... to ensure the Company delivers the best value for ... Ross , said the Company currently had an extensive ... discovery programs and academic partnerships and initiatives, and he ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... LAKE CITY, Feb. 29 DW Healthcare ... announced today the sale of one,of its ... Laboratory,Corporation of America(R) Holdings (LabCorp(R)), one of ... Salt Lake City, UT, Tandem,Labs is a ...
... Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... biopharmaceutical company focused on,endocrine therapy and oncology, ... the Company,s Senior Vice President, Administrative & ... accepted the position of,Vice President and Chief ...
... On Friday, February 29, the Johnson & Johnson ... the U.S., designed to improve how,practitioners deliver diabetes care ... be devoted to training community health,professionals., Diabetes affects ... billion a year -- about as much as the ...
Cached Biology Technology:AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The 10-user network license entitles ten users to access data f...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
Biology Products: